The global crohn's disease (cd) treatment market has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.76 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of crohn's disease, growing awareness of the disease, government initiatives, changing lifestyle.
The global crohn's disease (cd) treatment market is expected to see steady growth in the next few years. It will grow to $14.22 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn's disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.
The growth of the Crohn's disease (CD) treatment market is anticipated to be fueled by the rising prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) comprises a group of chronic inflammatory conditions that predominantly affect the gastrointestinal (GI) tract. CD treatment aims to alleviate symptoms, reduce inflammation, induce remission, and enhance the overall quality of life for individuals managing chronic inflammatory bowel disease. For instance, a study by BioMed Central Ltd. in May 2021 projected an expected increase in Inflammatory bowel disease cases in various regions, such as 69 thousand cases in Iran, 220 thousand cases in the Middle East, 2.2 million cases in India, and 4.5 million cases in East Asia between 2020 and 2035. As a result, the growing prevalence of inflammatory bowel diseases is a significant driver of the Crohn's disease (CD) treatment market.
Anticipated growth in the Crohn's disease treatment market can be attributed to the increasing number of clinical trials. Clinical trials are crucial for assessing the safety and effectiveness of new therapies, potentially leading to regulatory approvals and the introduction of novel treatment options for Crohn's disease (CD) patients. The demand for more efficient CD treatments encourages clinical trials, driven by the desire of patients and healthcare providers for improved outcomes with reduced side effects, thereby stimulating research and development endeavors. For example, the University of California reported 17 ongoing clinical trials focused on vedolizumab, oral ozanimod, and the long-term efficacy of mirikizumab for pediatric CD and ulcerative colitis patients, highlighting the proliferation of clinical trials in the fie
The growth of the Crohn's disease treatment market may be significantly impacted by the considerable expenses associated with treating this condition. Crohn's disease is a complex and highly variable ailment, making the development of effective treatments a challenging and costly endeavor. Creating new medications and therapies for Crohn's disease involves a complex and expensive process. As of December 2022, the initial cost of treating Crohn's disease averages around $30,000 within the first year, and individuals with inflammatory bowel disease face an annual average of $2,213 in out-of-pocket expenses, as reported by Everyday Health Inc. Consequently, the high costs of Crohn's disease treatment pose an obstacle to the expansion of the Crohn's disease (CD) treatment market.
Leading companies in the Crohn's disease (CD) treatment market are focused on the introduction of innovative technologies like IBDSENSE to maintain their market position. An example of this is the development of IBDSENSE by The IRR Chemistry Hub, an interdisciplinary hub based in Scotland. IBDSENSE is designed to enhance the diagnosis and monitoring of inflammatory bowel diseases, including Crohn's disease, through non-invasive methods. The technology utilizes fluorescence-based techniques to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples, aiming to enhance the patient experience and treatment options.
In June 2023, Merck & Co. Inc., a pharmaceutical company based in the United States, completed its acquisition of Prometheus Biosciences Inc. for a total of $10.8 billion. This strategic move by Merck & Co. is intended to broaden its range of products related to the treatment of immunological and inflammatory conditions. Prometheus Biosciences, a biotechnology company based in the United States, specializes in the development of drugs for inflammatory diseases, particularly in the areas of Crohn's disease and inflammatory bowel disease treatments.
Major players in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.
North America was the largest region in the Crohn’s disease (CD) treatment market in 2023. The regions covered in Crohn's disease (CD) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Crohn's disease (CD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary categories of drugs used in the treatment of Crohn's disease are antibiotics, aminosalicylates, corticosteroids, immunomodulators, and other types of medications. Antibiotics are drugs that combat bacterial infections by either killing the bacteria or inhibiting their growth and reproduction. These drugs can be administered orally or via injection, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
This report provides Crohn’s disease treatment market statistics, including Crohn’s disease treatment industry global market size, regional shares, competitors with a Crohn’s disease treatment market share, detailed Crohn’s disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the Crohn’s disease treatment industry. This Crohn’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The global crohn's disease (cd) treatment market is expected to see steady growth in the next few years. It will grow to $14.22 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn's disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.
The growth of the Crohn's disease (CD) treatment market is anticipated to be fueled by the rising prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) comprises a group of chronic inflammatory conditions that predominantly affect the gastrointestinal (GI) tract. CD treatment aims to alleviate symptoms, reduce inflammation, induce remission, and enhance the overall quality of life for individuals managing chronic inflammatory bowel disease. For instance, a study by BioMed Central Ltd. in May 2021 projected an expected increase in Inflammatory bowel disease cases in various regions, such as 69 thousand cases in Iran, 220 thousand cases in the Middle East, 2.2 million cases in India, and 4.5 million cases in East Asia between 2020 and 2035. As a result, the growing prevalence of inflammatory bowel diseases is a significant driver of the Crohn's disease (CD) treatment market.
Anticipated growth in the Crohn's disease treatment market can be attributed to the increasing number of clinical trials. Clinical trials are crucial for assessing the safety and effectiveness of new therapies, potentially leading to regulatory approvals and the introduction of novel treatment options for Crohn's disease (CD) patients. The demand for more efficient CD treatments encourages clinical trials, driven by the desire of patients and healthcare providers for improved outcomes with reduced side effects, thereby stimulating research and development endeavors. For example, the University of California reported 17 ongoing clinical trials focused on vedolizumab, oral ozanimod, and the long-term efficacy of mirikizumab for pediatric CD and ulcerative colitis patients, highlighting the proliferation of clinical trials in the fie
The growth of the Crohn's disease treatment market may be significantly impacted by the considerable expenses associated with treating this condition. Crohn's disease is a complex and highly variable ailment, making the development of effective treatments a challenging and costly endeavor. Creating new medications and therapies for Crohn's disease involves a complex and expensive process. As of December 2022, the initial cost of treating Crohn's disease averages around $30,000 within the first year, and individuals with inflammatory bowel disease face an annual average of $2,213 in out-of-pocket expenses, as reported by Everyday Health Inc. Consequently, the high costs of Crohn's disease treatment pose an obstacle to the expansion of the Crohn's disease (CD) treatment market.
Leading companies in the Crohn's disease (CD) treatment market are focused on the introduction of innovative technologies like IBDSENSE to maintain their market position. An example of this is the development of IBDSENSE by The IRR Chemistry Hub, an interdisciplinary hub based in Scotland. IBDSENSE is designed to enhance the diagnosis and monitoring of inflammatory bowel diseases, including Crohn's disease, through non-invasive methods. The technology utilizes fluorescence-based techniques to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples, aiming to enhance the patient experience and treatment options.
In June 2023, Merck & Co. Inc., a pharmaceutical company based in the United States, completed its acquisition of Prometheus Biosciences Inc. for a total of $10.8 billion. This strategic move by Merck & Co. is intended to broaden its range of products related to the treatment of immunological and inflammatory conditions. Prometheus Biosciences, a biotechnology company based in the United States, specializes in the development of drugs for inflammatory diseases, particularly in the areas of Crohn's disease and inflammatory bowel disease treatments.
Major players in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.
North America was the largest region in the Crohn’s disease (CD) treatment market in 2023. The regions covered in Crohn's disease (CD) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Crohn's disease (CD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary categories of drugs used in the treatment of Crohn's disease are antibiotics, aminosalicylates, corticosteroids, immunomodulators, and other types of medications. Antibiotics are drugs that combat bacterial infections by either killing the bacteria or inhibiting their growth and reproduction. These drugs can be administered orally or via injection, and they are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.
This report provides Crohn’s disease treatment market statistics, including Crohn’s disease treatment industry global market size, regional shares, competitors with a Crohn’s disease treatment market share, detailed Crohn’s disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the Crohn’s disease treatment industry. This Crohn’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The Crohn's disease (CD) treatment market consists of sales of Janus kinase inhibitors and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Crohn's Disease (CD) Treatment Market Characteristics3. Crohn's Disease (CD) Treatment Market Trends and Strategies32. Global Crohn's Disease (CD) Treatment Market Competitive Benchmarking33. Global Crohn's Disease (CD) Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Crohn's Disease (CD) Treatment Market
4. Crohn's Disease (CD) Treatment Market - Macro Economic Scenario
5. Global Crohn's Disease (CD) Treatment Market Size and Growth
6. Crohn's Disease (CD) Treatment Market Segmentation
7. Crohn's Disease (CD) Treatment Market Regional and Country Analysis
8. Asia-Pacific Crohn's Disease (CD) Treatment Market
9. China Crohn's Disease (CD) Treatment Market
10. India Crohn's Disease (CD) Treatment Market
11. Japan Crohn's Disease (CD) Treatment Market
12. Australia Crohn's Disease (CD) Treatment Market
13. Indonesia Crohn's Disease (CD) Treatment Market
14. South Korea Crohn's Disease (CD) Treatment Market
15. Western Europe Crohn's Disease (CD) Treatment Market
16. UK Crohn's Disease (CD) Treatment Market
17. Germany Crohn's Disease (CD) Treatment Market
18. France Crohn's Disease (CD) Treatment Market
19. Italy Crohn's Disease (CD) Treatment Market
20. Spain Crohn's Disease (CD) Treatment Market
21. Eastern Europe Crohn's Disease (CD) Treatment Market
22. Russia Crohn's Disease (CD) Treatment Market
23. North America Crohn's Disease (CD) Treatment Market
24. USA Crohn's Disease (CD) Treatment Market
25. Canada Crohn's Disease (CD) Treatment Market
26. South America Crohn's Disease (CD) Treatment Market
27. Brazil Crohn's Disease (CD) Treatment Market
28. Middle East Crohn's Disease (CD) Treatment Market
29. Africa Crohn's Disease (CD) Treatment Market
30. Crohn's Disease (CD) Treatment Market Competitive Landscape and Company Profiles
31. Crohn's Disease (CD) Treatment Market Other Major and Innovative Companies
35. Crohn's Disease (CD) Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
This report provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on crohn's disease (cd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for crohn's disease (cd) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:
1) By Drug Type: Antibiotics; Amino Salicylates; Corticosteroids; Immunomodulators; Other Drug Types2) By Route of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores
Key Companies Mentioned: Pfizer Inc.; Johnson and Johnson Ltd.; Merck and Co. Inc.; AbbVie Inc.; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer Inc.
- Johnson and Johnson Ltd.
- Merck and Co. Inc.
- AbbVie Inc.
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Abbott Laboratories
- GlaxoSmithKline Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Bausch Health Companies Inc.
- UCB S.A.
- Sun Pharmaceutical Industries Ltd.
- Perrigo Company PLC
- Dr. Reddy's Laboratories Ltd.
- Aurobindo Pharma Limited
- Cipla Limited
- Ferring B.V.
- Hikma Pharmaceuticals Plc
- Amneal Pharmaceuticals LLC
Methodology
LOADING...
